For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenue | 0 | 500 | - | - |
| Cost of revenue | 0 | 132 | - | - |
| Research and development | 4,270 | 5,373 | 3,930 | 5,920 |
| General and administrative | 6,045 | 5,494 | 7,272 | 6,744 |
| Other income | 300 | - | - | - |
| Loss from operations | -10,015 | -10,499 | -11,202 | -12,664 |
| Interest income | 504 | 589 | 659 | 686 |
| Interest expense | 28 | 24 | 180 | 339 |
| Changes in the fair value of warrants | 196 | -101 | 416 | -120 |
| Foreign currency transaction (loss)/gain, net | 1,873 | -5,326 | -2,765 | 2,545 |
| Benefit from research and development tax credit | 446 | 745 | 185 | 474 |
| Net loss before income tax | -7,024 | -14,616 | -12,887 | -9,417 |
| Income tax benefit | 0 | 0 | - | - |
| Net loss | -7,024 | -14,616 | -12,887 | -9,417 |
| Other comprehensive income/(loss) - foreign currency translation adjustments, net of tax | -2,267 | 6,647 | 3,559 | -2,846 |
| Total comprehensive loss | -9,291 | -7,969 | -9,328 | -12,263 |
| Earnings per share, basic | -0.01 | -0.02 | -0.02 | -0.013 |
| Earnings per share, diluted | -0.01 | -0.02 | -0.02 | -0.013 |
| Weighted average number of shares outstanding, basic | 799,947,013 | 799,435,329 | 784,279,387 | -10,174,108.333 |
| Weighted average number of shares outstanding, diluted | 799,947,013 | 799,435,329 | 784,279,387 | -10,174,108.333 |
Mereo BioPharma Group plc (MREO)
Mereo BioPharma Group plc (MREO)